What is Flex Pharma?
Flex Pharma, Inc. is a biotechnology company dedicated to developing and commercializing novel products aimed at treating muscle cramps and spasms. These conditions are often associated with neurological disorders and exercise-induced muscle cramps. The company operates across two primary segments: Consumer Operations, which offers products like HOTSHOT for immediate cramp relief, and Drug Development, focusing on pharmaceutical candidates. Its lead drug candidate, FLX-787, is an investigational transient receptor potential ion channel activator currently in exploratory Phase 2 clinical trials for conditions such as multiple sclerosis and amyotrophic lateral sclerosis. The company's strategic approach combines direct-to-consumer offerings with advanced pharmaceutical research, positioning it uniquely within the healthcare market.
How much funding has Flex Pharma raised?
Flex Pharma has raised a total of $86.4M across 1 funding round:
Stock Offering
$86.4M
Stock Issuance/Offering (2015): $86.4M, investors not publicly disclosed
What's next for Flex Pharma?
The substantial enterprise-level funding and recent strategic investment provide Flex Pharma with the necessary capital to advance its drug development pipeline, particularly FLX-787, through critical clinical trial phases. This financial backing is expected to accelerate research and development efforts, potentially leading to regulatory submissions and market entry for its therapeutic candidates. Furthermore, the investment will likely support the expansion of its consumer product lines, such as HOTSHOT, enhancing market reach and brand visibility. Flex Pharma's ability to attract significant backing suggests a promising outlook for its innovative solutions in both the pharmaceutical and consumer health sectors, enabling the company to scale operations and pursue its mission of improving patient outcomes.
See full Flex Pharma company page
